Bleeding is the most common adverse drug event associated with anticoagulants and life-threatening bleeding requires emergent reversal of the anticoagulant effect.  This session will cover reversal strategies for all anticoagulants but will focus on the direct oral anticoagulants (DOACs).  It will also cover when to resume anticoagulation after a major bleeding event.   

Objectives:

As a result of this educational regularly scheduled series, learners will be able to:

1. Describe available reversal agents for oral anticoagulants
2. Compare the data for prothrombin complex concentrates (PCC) and andexanet alfa for reversal of direct oral anticoagulants (DOACs)
3. Identify when to resume anticoagulation after a major bleeding event